Follow-up of collagen crosslink excretion in patients with oral squamous cell carcinoma and analysis of tissue samples

Abstract

The presence of an oral squamous cell carcinoma (OSCC) may be associated with increased urinary excretion of the markers of collagen degradation, hydroxylysylpyridinoline (HP) and lysylpyridinoline (LP). We investigated the possibility of these markers predicting the presence of active disease. Patients from a current study on HP and LP were included as follows: Group 1a (OSCC with confirmed mandibular bony infiltration, n = 12). group 1b (group 1a patients >6 months after successful treatment), group 2a (OSCC without evidence of mandibular bone infiltration, n = 8), group 2b (group 2a patients >6 months after successful treatment), group 3a (recurrent OSCC, n = 8), group 3b (group 3a patients >6 weeks later, symptoms unchanged) and group 4 (control group, n = 74). Tissue samples from tumour tissue and adjacent healthy mucosa were additionally investigated for HP and LP concentrations (n = 8). The decrease in the urinary concentrations of HP and LP was statistically significant between groups 1a and 1b (P < 0.001 for HP and LP), but not between groups 2a and 2b (P = 0.07 for HP and LP), while values in groups 1b and 2b were within the normal range. When comparing groups 3a and 3b, a significant increase was observed for LP (P = 0.050), but not HP (P = 0.208). In conclusion, successful treatment of OSCC with bony involvement may be associated with a reduction of urinary HP and LP, whereas ongoing disease may result in an increase of LP. HP and LP may both be useful markers of tumour progression in patients with OSCC. © 2003 Cancer Research UK.